RT Journal Article
SR Electronic
T1 A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.29.22279317
DO 10.1101/2022.08.29.22279317
A1 Lien, Chia En
A1 Liu, Ming-Che
A1 Wang, Ning-Chi
A1 Liu, Luke Tzu-Chi
A1 Wu, Chung-Chin
A1 Tang, Wei-Hsuan
A1 Lian, Wei-Cheng
A1 Huang, Kuan-Ying A.
A1 Chen, Charles
YR 2022
UL http://medrxiv.org/content/early/2022/08/30/2022.08.29.22279317.abstract
AB Background The use of variant-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine as a booster is being evaluated to overcome reduced neutralisation of variants induced by the original SARS-CoV-2 vaccine and waning protection over time.Methods This is a phase one, prospective, randomized, and open-labeled trial to study the safety and immunogenicity of a booster dose consisting of a subunit vaccine based on the stabilized prefusion SARS-CoV-2 spike protein, MVC-COV1901 or its Beta version, MVC-COV1901-Beta. One-hundred and seven participants aged ≥18 and <55 years, who received two or three prior doses of MVC-COV1901 vaccines, were enrolled and were to receive a booster dose of either 15 mcg of MVC-COV1901, 15 mcg or 25 mcg of MVC-COV1901-Beta in 1:1:1 ratio. The primary endpoints were the incidences of adverse events and immunogenicity of the booster dose from Visit 2 (the day of the booster) to Visit 5 (four weeks after the booster). Cellular immunity was also investigated with memory B cell (MBC) and T cell assays.Findings Adverse reactions after either MVC-COV1901 or MVC-COV1901-Beta booster doses after two or three doses of MVC-COV1901 were comparable and mostly mild and transient. At four weeks after the booster dose, participants with two prior doses of MVC-COV1901 exhibited numerically higher levels of neutralising antibodies against SARS-CoV-2 or Beta variant than participants with three prior doses of MVC-COV1901 regardless of the type of booster used. However, compared to 15 mcg of MVC-COV1901, 25 mcg of MVC-COV1901-Beta significantly improved neutralising antibody titre against Beta variant and BA.4/BA.5 Omicron variant pseudoviruses. The booster dose also significantly increased the proportion of spike-specific MBCs, including those of Beta and Omicron variants.Interpretation MVC-COV1901-Beta can be effectively used as a booster dose against SARS-CoV-2, including the circulating BA.4/BA.5 Omicron variant.Funding Medigen Vaccine Biologics CorporationCompeting Interest StatementC. E. L., L. T.-C.- L., C.-C. W., W.-H. T., W.-C. L., and C. C. are employees of Medigen Vaccine Biologics Corporation. M.-C. L., N.-C. W., and K.-Y. A. H. declared no conflict of interest. All authors have reviewed and agreed to the final version of the manuscript. Clinical TrialNCT05216601Funding StatementThis study was funded by Medigen Vaccine Biologics Corporation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Taipei Medical University Hospital (Taipei, Taiwan) gave ethical approval for this work IRB of Tri-Service General Hospital (Taipei, Taiwan) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing is not applicable to this study, as it is an interim analysis of an ongoing clinical trial.